Avila Therapeutics

Celgene to acquire Avila Therapeutics

Thursday, January 26, 2012 02:46 PM

Summit, N.J.-based Celgene will acquire privately held Avila Therapeutics of Bedford, Mass., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, for $350 million in cash.

More... »


Avila names Hirsch CFO

Tuesday, July 12, 2011 10:14 AM

Avila Therapeutics, a biotechnology company developing targeted covalent drugs, has named Andrew Hirsch its first chief financial officer.

More... »



CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs